FDA Grants Rare Pediatric Disease Designation to 177Lu-omburtamab-DTPA for Medulloblastoma

Article

Pediatric patients with medulloblastoma may experience benefit from 177Lu-omburtamab-DTPA, which was granted a rare pediatric disease designation by the FDA.

177Lu-omburtamab-DTPA was granted a rare pediatric disease designation (RPDD) by the FDA for patients with medulloblastoma, according to a press release from developer Y-mAbs Therapeutics, Inc.

The monoclonal B7-H3 antibody that has been radiolabeled with lutetium-177 is currently under investigation as part of a multicenter phase 1/2 study (NCT04167618) in pediatric patients with recurrent or refractory medulloblastoma, as well as in a multicenter phase 1 study (NCT04315246) in adult patients with B7-H3–positive central nervous system tumors or leptomeningeal metastases. Investigators stated that both indications may work to address unmet needs within both patient populations.

“The RPDD makes us eligible for a Priority Review Voucher (“PRV”) upon potential approval of the biologics license application for this rare pediatric cancer. Among our leading compounds under development, four now have RPDDs, and this designation for 177Lu-omburtamab-DTPA further increase our chances of ultimately receiving multiple PRVs,” Thomas Gad, founder, chairman, and president of Y-mAbs Therapeutics, said in a press release.

The pediatric study, which has an estimated enrollment of 40 patients, utilized a 3+3 sequential group design in part 1, which was a dose-escalation phase. Patients were administered a dosimetry dose that was followed with the maximum of 2 5-week cycles of treatment with intracerebroventricular omburtamab. In part 2 of the study, patients included in the cohort expansion received a maximum of 5 5-week cycles and intracerebroventricular omburtamab based on the recommended dose from part 1. The end of treatment will occur within 5 weeks of the last cycle, wherein patients will enter the follow up period. Patients will be followed for up to 2 years following the last dose of treatment.

Moreover, the adult study has an estimated enrollment of 63 patients. In the dose-escalation portion of the study, a 3+3 sequential group design was utilized, wherein patients were treated with a dosimetry dose followed by a maximum of 5 5-week cycles of treatment. In the cohort-expansion portion, patients were given the recommended dose from part 1 until experiencing leptomeningeal metastatic progression, unacceptable toxicity, or up to a maximum of 5 cycles. Notably, the number of cycles were determined based on the final cycle, after which patients entered the follow up period. Patients were followed for up to 1 year following the first dose for part 1 and 2 years after the first dose for part 2.

Omburtamab has been exclusively license to Memorial Sloan Kettering Cancer Center, leading to a licensing arrangement in which the institution has institutional financial interests in the therapy.

Reference

Y-mAbs’ 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Granted Rare Pediatric Disease Designation by FDA. News release. Y-mAbs Therapeutics. October 7, 2021. Accessed October 11, 2021. https://bit.ly/30fGIQ6

Recent Videos
The act of asking for help is critical to finding mentors who can help one advance in the brain cancer field, according to Yoshie Umemura, MD.
Through multidisciplinary collaboration, Yoshie Umemura, MD, and colleagues were able to organize the Gliofocus trial in brain cancer relatively fast.
Yoshie Umemura, MD, discusses how multiple departments can positively impact a patient with brain cancer during their visit to a medical center.
Antibody-drug conjugates and small molecule inhibitors may show utility in the neuro-oncology field, according to Nader Sanai, MD.
The phase 3 Gliofocus trial aims to meaningfully improve survival and quality of life with niraparib among patients with newly diagnosed glioblastoma.
Findings from a proof-of-concept study show a potential survival benefit with niraparib/radiotherapy in patients with newly diagnosed glioblastoma.
Accelerated approval of afami-cel may expand access to therapy for patients who are unable to live near certain treatment centers.
Treatment with afami-cel may offer improved quality of life to patients with metastatic synovial sarcoma compared with continuous chemotherapy.
ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.